

Dr Peter Jackson

Dr Peter Jackson is chair of the UK AMR Centre Consortium Steering Group, Executive Director of AMR Centre Ltd, and a member of the Joint Oversight Committee of the transatlantic CARB-X initiative.

An experienced life sciences entrepreneur, Dr Jackson is the founder of five life sciences ventures:

RedX Pharma plc – an emerging pharmaceutical company focused on developing new immunotherapy, oncology and anti-infective drugs;

ADC Biotechnology Ltd – focused on production of new antibody-based cancer therapeutics;

Yprotech Ltd – focused on development of new chemistry processes for pharmaceuticals and agrochemicals;

RedAg Crop Protection – developing the next generation of fungicides, herbicides and insecticides to overcome emerging resistant organisms in agriculture; and

Bivictrix Therapeutics – a new start up developing innovative precision medicine approaches to Leukemia.

Dr Jackson has over 25 years in the sector, previously holding senior executive roles as a Commercial Director and then head of Avecia's Pharmaceutical Products business unit, following senior commercial and R&D positions at Zeneca and ICI.